Risperdal CONSTA (risperidone)

Risperdal CONSTA is a long-acting injectable (LAI) formulation of the atypical antipsychotic risperidone, developed by Janssen (a Johnson & Johnson company) and Alkermes. It utilizes Alkermes' proprietary Medisorb® microsphere technology, where risperidone is encapsulated in a biodegradable polylactide-co-glycolide (PLG) polymer. This formulation allows for the sustained release of the drug over a two-week period following intramuscular injection, overcoming the need for daily oral dosing and improving treatment adherence. Risperidone acts primarily as a potent antagonist at dopamine D2 and serotonin 5-HT2A receptors. Risperdal CONSTA was the first long-acting atypical antipsychotic to receive FDA approval, initially for the treatment of schizophrenia in 2003 and subsequently for the maintenance treatment of bipolar I disorder as both monotherapy and adjunctive therapy to lithium or valproate.

Brand names

Risperdal CONSTA

Other names

risperidone long-acting injectionrisperidone LAIRLAIrisperidone microspheres